Paper1640487
Multiparametric prognostic evaluation of biological factors in primary breast cancer.
Spyratos F and 9 others. J Natl Cancer Inst, 1992. Cited by 120 papers, by iCite.
Cite this record
ConductScience Library. Multiparametric prognostic evaluation of biological factors in primary breast cancer. Papers, record 1640487. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1640487
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Cathepsin D | Major topic |
| DNA, Neoplasm | Major topic |
| Urokinase-Type Plasminogen Activator | Major topic |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Cell Division | |
| Chi-Square Distribution | |
| Female | |
| Flow Cytometry | |
| Humans | |
| Lymphatic Metastasis | |
| Middle Aged | |
| Multivariate Analysis | |
| Prognosis | |
| Retrospective Studies |
Source PubMed
Cited by16
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 120 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 30646864 | Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. | BMC Cancer | 2019 | https://conductscience.org/library/papers/30646864 | PubMed |
| 28922402 | New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes. | PLoS One | 2017 | https://conductscience.org/library/papers/28922402 | PubMed |
| 25677449 | uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. | Breast Cancer Res | 2014 | https://conductscience.org/library/papers/25677449 | PubMed |
| 22350496 | Patients with metastatic breast cancer using bevacizumab as a treatment: is there still a role for it? | Curr Treat Options Oncol | 2012 | https://conductscience.org/library/papers/22350496 | PubMed |
| 10408848 | Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10408848 | PubMed |
| 10389993 | Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10389993 | PubMed |
| 10098758 | Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients. | Br J Cancer | 1999 | https://conductscience.org/library/papers/10098758 | PubMed |
| 9836475 | External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9836475 | PubMed |
| 9662256 | Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MB-231 human breast cancer cells stably expressing the oestrogen receptor. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9662256 | PubMed |
| 9652768 | Prognostic value of urokinase plasminogen activator in primary breast carcinoma: comparison of two immunoassay methods. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9652768 | PubMed |
| 9591698 | Prognostic significance of cell cycle parameters in infiltrative ductal breast carcinoma. | J Clin Lab Anal | 1998 | https://conductscience.org/library/papers/9591698 | PubMed |
| 9528837 | Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. | Br J Cancer | 1998 | https://conductscience.org/library/papers/9528837 | PubMed |
| 9195286 | Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. | Invest New Drugs | 1997 | https://conductscience.org/library/papers/9195286 | PubMed |
| 8944332 | Influence of the extraction procedure on plasminogen activator inhibitor-2 (PAI-2) and urokinase receptor (uPAR) assays in breast cancer tissues. | Breast Cancer Res Treat | 1996 | https://conductscience.org/library/papers/8944332 | PubMed |
| 8297742 | Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. | Br J Cancer | 1994 | https://conductscience.org/library/papers/8297742 | PubMed |
| 7819033 | Stromal cell cathepsin D expression and long-term survival in breast cancer. | Br J Cancer | 1995 | https://conductscience.org/library/papers/7819033 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CTSD | 1509 | PubTator's text mining | https://conductscience.org/library/genes/1509 | NCBI Gene |
| PLAU | 5328 | PubTator's text mining | https://conductscience.org/library/genes/5328 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/1640487
GET https://conductscience.org/api/papers/v1/1640487/authors